X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (158) 158
oncology (137) 137
male (117) 117
female (113) 113
aged (102) 102
index medicus (100) 100
lung neoplasms - drug therapy (99) 99
middle aged (87) 87
carcinoma, non-small-cell lung - drug therapy (82) 82
electricity (81) 81
chemotherapy (79) 79
adult (76) 76
basic electric elements (69) 69
electric solid state devices not otherwise provided for (65) 65
lung cancer (65) 65
semiconductor devices (65) 65
lung neoplasms - pathology (56) 56
performing operations (52) 52
transporting (52) 52
antineoplastic combined chemotherapy protocols - therapeutic use (51) 51
respiratory system (51) 51
gefitinib (50) 50
aged, 80 and over (49) 49
cancer (49) 49
treatment outcome (46) 46
lining machines (45) 45
printing (45) 45
stamps (45) 45
typewriters (45) 45
cisplatin (43) 43
lung cancer, non-small cell (42) 42
physics (42) 42
antineoplastic agents - therapeutic use (41) 41
lung neoplasms - mortality (40) 40
materials for surfaces used in printing machines for printing,inking, damping, or the like (39) 39
preparing such surfaces for use and conserving them (39) 39
printing plates or foils (39) 39
non-small cell lung cancer (37) 37
lung neoplasms - genetics (34) 34
survival (34) 34
carcinoma, non-small-cell lung - mortality (33) 33
chemistry (31) 31
metallurgy (31) 31
mutation (31) 31
neoplasm staging (30) 30
quinazolines - therapeutic use (30) 30
carcinoma, non-small-cell lung - pathology (29) 29
retrospective studies (29) 29
processes for the manufacture or reproduction of printingsurfaces (28) 28
carboplatin (27) 27
survival rate (27) 27
apparatus therefor (26) 26
pulmonary/respiratory (26) 26
carcinoma, non-small-cell lung - genetics (25) 25
cisplatin - administration & dosage (25) 25
electrolytic or electrophoretic processes (25) 25
hematology, oncology and palliative medicine (25) 25
epidermal growth factor (24) 24
prognosis (24) 24
receptor, epidermal growth factor - genetics (24) 24
research (24) 24
care and treatment (23) 23
erlotinib (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
non-small-cell lung cancer (22) 22
therapy (22) 22
trial (22) 22
general tagging of cross-sectional technologies spanning over several sections of the ipc (21) 21
general tagging of new technological developments (21) 21
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (21) 21
tumors (21) 21
docetaxel (20) 20
oncology, experimental (20) 20
survival analysis (20) 20
technical subjects covered by former uspc (19) 19
technical subjects covered by former uspc cross-reference artcollections [xracs] and digests (19) 19
analysis (18) 18
antineoplastic agents - adverse effects (18) 18
combined modality therapy (18) 18
lung neoplasms - therapy (18) 18
prospective studies (18) 18
adenocarcinoma (17) 17
clinical trials (17) 17
japan (17) 17
open-label (17) 17
phase-iii (17) 17
adenocarcinoma - drug therapy (16) 16
patients (16) 16
apparatus specially adapted therefor (15) 15
chemoradiotherapy (15) 15
cinematography (15) 15
electrography (15) 15
follow-up studies (15) 15
holography (15) 15
materials therefor (15) 15
metaanalysis (15) 15
mutations (15) 15
originals therefor (15) 15
photography (15) 15
photomechanical production of textured or patterned surfaces,e.g. for printing, for processing of semiconductordevices (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Journal Article
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 5/2019, Volume 24, Issue 5, pp. 461 - 467
Journal Article
Journal Article
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 1955 - 11
Journal Article
International Journal of Clinical Oncology, ISSN 1341-9625, 01/2019, Volume 24, Issue 1, pp. 41 - 45
The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances... 
Re-biopsy | Lung cancer | Treatment | SPATIOTEMPORAL T790M HETEROGENEITY | OPEN-LABEL | PROSPECTIVE FEASIBILITY | CISPLATIN-BASED CHEMOTHERAPY | LOW-VOLUME HYDRATION | EGFR-MUTANT | ONCOLOGY | ALECTINIB | MUTATIONS | 1ST-LINE | EXPRESSION
Journal Article
Experimental Cell Research, ISSN 0014-4827, 03/2014, Volume 322, Issue 1, pp. 168 - 177
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2004, Volume 22, Issue 19, pp. 3860 - 3867
Purpose The role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer (NSCLC) remains to be defined. This study was aimed at... 
SURGERY | UFT | THERAPY | ONCOLOGY | BIAS | CLINICAL-TRIALS | STAGE-I | Carcinoma, Non-Small-Cell Lung - therapy | Reproducibility of Results | Chemotherapy, Adjuvant - adverse effects | Humans | Survival Rate | Treatment Outcome | Combined Modality Therapy | Lung Neoplasms - therapy | Randomized Controlled Trials as Topic
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1823 - 1833
Journal Article
Journal Article
Respiratory Investigation, ISSN 2212-5345, 07/2019, Volume 57, Issue 4, pp. 330 - 336
Approximately 20–25% of non-small-cell lung cancer (NSCLC) is diagnosed when the disease has progressed to clinical stage III. At this stage, and even if the... 
Stage III | Immune checkpoint inhibitor | Durvalumab | Chemoradiotherapy | Lung cancer
Journal Article